Abstract
The landscape of invasive Candida infections in patients with hematologic malignancy has evolved due to the adoption of anti-fungal prophylaxis, advances in oncological therapies, and developments in antifungal therapies and diagnostics. Despite these scientific gains, the morbidity and mortality caused by these infections remain unchanged, highlighting the importance of an updated understanding of its epidemiology. Non-albicans Candida species are now the predominant cause of invasive candidiasis in patients with hematological malignancy. This epidemiological shift from Candida albicans to non-albicans Candida species is partially a consequence of selective pressure from extensive azole use. Further analysis of this trend suggests other contributing factors including immunocompromise caused by the underlying hematologic malignancy and the intensity of its associated treatments, oncological practices, and regional or institution specific variables. This review characterizes the changing distribution of Candida species in patients with hematologic malignancy, describes the causes driving this change, and discusses clinical considerations to optimize management in this high-risk patient population.
Original language | English (US) |
---|---|
Pages (from-to) | 885-892 |
Number of pages | 8 |
Journal | Mycopathologia |
Volume | 188 |
Issue number | 6 |
DOIs | |
State | Published - Dec 2023 |
Keywords
- Antifungal
- Candidemia
- Hematologic malignancy
- Hematopoietic stem cell transplant
- Non-albicans Candida
ASJC Scopus subject areas
- Microbiology
- Applied Microbiology and Biotechnology
- Agronomy and Crop Science
- veterinary (miscalleneous)